Loading
Intersect ENT, Inc. Stock: price and insider trades · United States
Intersect ENT, Inc.: what insiders have been doing
Intersect ENT, Inc., founded in 2003, is a Healthcare & Pharma company based in Menlo Park, United States. Its directors and officers file their transactions with SEC (Form 4). Intersect ENT, Inc. has had no insider filing for more than a year; the last one goes back to 16 May 2022.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
24
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$91.9M
Gross profitUS$66.1M72% margin
Net income-US$137.4M-149.5% margin
Last declaration on 16 May 2022
Declarations24 total
39,700 shares@ US$28.2577.0% of flowCommon StockSEC:0001562180-22-004071:0
41,999 shares@ US$28.2594.3% of flowCommon StockSEC:0001562180-22-004074:0
3,239 shares@ US$28.25100.0% of flowCommon StockSEC:0001562180-22-004073:0
16,383 shares@ US$28.25100.0% of flowCommon StockSEC:0001562180-22-004069:0
20,890 shares@ US$28.25100.0% of flowCommon StockSEC:0001562180-22-004067:0
57,230 shares@ US$28.2591.1% of flowCommon StockSEC:0001562180-22-004076:0
8,837 shares@ US$28.25100.0% of flowCommon StockSEC:0001562180-22-004070:0
28,165 shares@ US$28.2594.3% of flowCommon StockSEC:0001562180-22-004075:0
36,738 shares0Common StockSEC:0001562180-22-001159:0
106,540 shares0Common StockSEC:0001562180-22-001158:0
25,895 shares0Common StockSEC:0001562180-22-001098:0
17,429 shares0Common StockSEC:0001562180-22-001103:0
2,935 shares@ US$26.90725.7% of flowCommon StockSEC:0001562180-21-007463:0
1,957 shares@ US$26.90725.7% of flowCommon StockSEC:0001562180-21-007464:0
6,346 shares@ US$26.93888.9% of flowCommon StockSEC:0001562180-21-007368:0
19,243 shares@ US$19.743623.0% of flowCommon StockSEC:0001562180-21-005070:0
3,239 shares0Common StockSEC:0001562180-21-004111:0
3,239 shares0Common StockSEC:0001562180-21-004113:0
3,239 shares0Common StockSEC:0001562180-21-004116:0
3,239 shares0Common StockSEC:0001562180-21-004112:0
3,603 sharesCommon StockSEC:0001562180-16-001386:0
3,603 sharesCommon StockSEC:0001562180-16-001386:1
8,000 sharesCommon StockSEC:0001562180-16-001352:0
12,500 sharesCommon StockSEC:0001562180-16-001352:1
24 of 24 declarations
About Intersect ENT, Inc.
Intersect ENT, Inc. was a United States medical technology company focused on ear, nose, and throat (ENT) care and formerly listed on the NASDAQ market in the United States. Founded in 2003, the company was headquartered in Menlo Park, California, in the heart of Silicon Valley. Its strategic niche was straightforward: to improve outcomes for patients with chronic sinus disease through localized drug-delivery devices and related ENT solutions used by surgeons.
The company’s core business centered on steroid-eluting implants and sinus-treatment technologies. Its best-known products included PROPEL and SINUVA, two FDA-cleared implant platforms designed to deliver medication locally in connection with ENT procedures. Intersect ENT also broadened its portfolio through the October 2020 acquisition of Fiagon AG Medical Technologies, which added electromagnetic surgical navigation capabilities and complementary ENT offerings such as the VENSURE sinus dilation balloon and CUBE navigation system. This acquisition strengthened the company’s product breadth and helped extend its geographic reach beyond its original U.S.-centric footprint.
Read moreShow less
From a competitive standpoint, Intersect ENT operated in a specialized but attractive segment of medtech. The company differentiated itself through a focused ENT franchise, a localized drug-delivery approach, and devices designed to complement rather than replace surgical treatment. Its competitive positioning was supported by the underlying demand for less invasive, more targeted therapies in chronic rhinosinusitis. While the business was primarily anchored in the United States, the Fiagon acquisition added a more international dimension and expanded its commercial and clinical reach.
A major recent milestone was Medtronic’s announcement in August 2021 that it would acquire Intersect ENT, followed by completion of the transaction in May 2022. As a result, Intersect ENT is no longer an independent publicly traded company today. That said, the company remains relevant for investors monitoring historical SEC filings, including Form 4 insider transaction disclosures filed before the acquisition. For French-speaking investors, Intersect ENT represents a classic medtech niche player: focused, clinically differentiated, and ultimately absorbed into a larger global platform after building a recognized position in ENT care on the NASDAQ in the United States.
